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Abstract
Background: Because cell signaling and cell metabolic pathways are executed through proteins, protein signatures in
primary tumors are useful for identifying key nodes in signaling networks whose alteration is associated with malignancy
and/or clinical outcomes. This study aimed to determine protein signatures in primary lung cancer tissues.
Methodology/ Principal Findings: We analyzed 126 proteins and/or protein phosphorylation sites in case-matched normal
and tumor samples from 101 lung cancer patients with reverse-phase protein array (RPPA) assay. The results showed that 18
molecules were significantly different (p,0.05) by at least 30% between normal and tumor tissues. Most of those molecules
play roles in cell proliferation, DNA repair, signal transduction and lipid metabolism, or function as cell surface/matrix
proteins. We also validated RPPA results by Western blot and/or immunohistochemical analyses for some of those
molecules. Statistical analyses showed that Ku80 levels were significantly higher in tumors of nonsmokers than in those of
smokers. Cyclin B1 levels were significantly overexpressed in poorly differentiated tumors while Cox2 levels were
significantly overexpressed in neuroendocrinal tumors. A high level of Stat5 is associated with favorable survival outcome
for patients treated with surgery.
Conclusions/ Significance: Our results revealed that some molecules involved in DNA damage/repair, signal transductions,
lipid metabolism, and cell proliferation were drastically aberrant in lung cancer tissues, and Stat5 may serve a molecular
marker for prognosis of lung cancers.
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Introduction
Molecular profiling of lung cancer through gene array assays for
mRNA and microRNA has led to the identification of molecular
signatures that are potentially useful for predicting patient survival
and disease relapse and/or response to individual chemothera-
peutic drugs based on hierarchical and probabilistic clustering of
mRNA [1] and microRNA levels [2]. Also, studies of single-
nucleotide polymorphisms of genomic DNA have led to the
identification of potential gene loci in the chromosome 15q25
region [3] that encode nicotinic acetylcholine receptor subunit
genes that are highly associated with lung cancer susceptibility.
Nevertheless, for most genes, there is no significant correlation
between mRNA and protein levels [4]. Thus, the key signaling
pathways that reflect the disease-transforming processes remain to
be identified. Because most signal transduction and pathway
regulation are conducted by proteins undergoing posttranscrip-
tional modification, such as phosphorylation, which cannot be
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31087detected by DNA, mRNA, or miRNA analyses, characterization
of protein levels and protein phosphorylation status is needed to
obtain protein signatures that reflect functional and/or metabolic
changes in lung cancer and/or response to therapeutic agents,
such as kinase inhibitors.
Efforts have been made to determine protein signatures in lung
cancer by using two-dimensional gel electrophoresis and subse-
quent protein identification by mass spectrometry assay or by
using direct mass spectrometry analyses [5]. While this technology
is useful for identification of proteins differentially expressed in
tumor tissues, it is likely not adaptable to the rapid-throughput
assays necessary for clinical application because of the time-
intensive processes involved, the possibility of signal contamina-
tions due to thousands of data points involved in the analysis, and
the possible corruption of data sets due to experimental design
issues [6].
The recent advent of protein microarray technology may allow
us to identify critical nodes or interactions within the network of
cellular signaling pathways. The advantage of the RPPA method is
that a single test probe (antibody) is used for each array, so the
testing condition is consistent for each antibody, thereby providing
better reproducibility and sensitivity than other protein array
techniques. With thoroughly assessed and validated antibodies, an
RPPA can be used to detect signal differences in a few thousand
molecules in testing samples [7]. Therefore, this technology is
useful for monitoring changes in protein levels and protein
phosphorylation over time, before and after treatment, between
tumor and normal tissues, and between responders and non-
responders. Once differential targets are identified, it is possible to
use conventional methods to test a small subset of molecular
biomarkers for prognosis or prediction of treatment response. To
this end, we collected case-matched normal and malignant lung
tissue samples of 101 patients and determined their protein levels
and protein phosphorylation statuses using RPPA method and 126
antibodies. Here, we report that several molecular nodes that are
critical in cell attachment, DNA repair, cell proliferation, and
signal transduction were differentially expressed between normal
and cancerous tissues, some of them were associated with clinical
parameters, including survival outcomes.
Results
Patient and Tumor Characteristics
We collected case-matched normal and malignant lung tissue
samples from 101 patients. Characteristics of those patients and
the tumors are summarized in Table 1. The patients were ages 42–
86 y, with a mean age of 65 y, and 55% were women. Most of the
patients (93%) were Caucasian. Adenocarcinoma and squamous
cell carcinoma accounted for 56% and 31% of histological types,
respectively. The majority of patients (66%) had stage I disease.
About 50% of tumors were poorly differentiated, and 40% were
moderately differentiated. Ninety patients (89%) had a history of
tobacco use/smoking. Twenty-four patients had neoadjuvant
chemotherapy, and one had neoadjuvant radiotherapy.
Differential Expression between Tumor and Normal
Tissues Revealed by RPPA
For each sample and each antibody, the signal in the RPPA
assays was compared between normal and tumor tissues. The
signal difference between normal and tumor tissues was calculated
as follows: [(mean of tumor tissues2mean of normal tissues)/
(mean of normal tissues6100%)]. Of 126 proteins or phosphor-
ylation sites analyzed, 18 had signal differences that were greater
than 30% and were statistically significant (p,0.05) in all the
normal and tumor samples analyzed (Table 2). These 18 molecules
can be categorized as molecules associated with cell proliferation
(cyclin B1), adaptor molecules in signal transduction (14-3-3zeta,
IRS1-pS307, and IGFBP2), molecules in lipid metabolism (COX2
and ACC-pS79), molecules involved in DNA damage responses
(Ku80, CHK2, and ATM), cell surface or matrix molecules
(caveolin 1, CD31, and collagen type VI), and molecules in
signaling pathways (PI3K/AKT pathway: PI3K-p85, mTOR, and
S6K; Src/Stat pathway: Stat5 and Src; and MAP kinase pathway:
p38-pT180). The signal intensities for cyclin B1, IGFBP2, and
caveolin 1 in tissue samples from each case are shown as examples
in Fig. 1. Most of these molecules have been reported to play
critical roles in various cancers or to have altered expression in
various cancers. For example, loss of caveolin 1 expression [8,9]
and overexpression of cyclin B1 [10,11] in lung cancer tissue have
previously been reported in studies with cDNA arrays and
immunohistochemical analyses.
Because 88 of the 101 cases in this study were either
adenocarcinoma or squamous cell carcinoma, we analyzed
whether these 18 molecules were significantly different between
normal and tumor tissue samples for the two major subtypes of
non-small cell lung cancers. The results showed that 13 of the 18
molecules were significantly different between normal and tumor
tissue for both adenocarcinoma and squamous cell carcinoma
(p#0.05, Table S2), a finding similar to that observed when all
samples were analyzed together. Two molecules (COX2 and S6)
were not significantly different when adenocarcinoma and
squamous cell carcinoma were analyzed separately, while PI3K-
p85, Src, and mTOR remained significantly different between
normal and tumor tissues in adenocarcinoma but not in squamous
Table 1. Clinical Information.
Pathology Cases (numbers) Ages (year) Stage Differentiation* Sex# Race1
I II III IV P M W M F W AA His
Adenocarcinoma 57 44–86 36 9 11 1 27 24 6 23 34 53 2 2
Squamous Ca 31 42–82 20 6 5 0 17 13 1 19 12 29 1 1
Neuroendocrine 5 51–78 4 1 0 0 01414 41 0
Large Cell/NSCLC 8 59–69 7 0 1 0 62026 80 0
Total 101 65 (mean) 67 16 17 1 50 40 11 45 56 94 4 3
*P, M, W, stand for poorly, moderately and well differentiated, respectively.
#M and F stand for male and female, respectively.
1W, AA and His stand for White, African American, and Hispanic, respectively.
doi:10.1371/journal.pone.0031087.t001
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are more critical in adenocarcinoma than in squamous cell
carcinoma or whether this finding was due to smaller numbers of
squamous cell carcinoma samples in the study is not clear.
Validation of RPPA Data
We performed Western blotting analysis on molecules whose
expressions were changed in relatively a large number of tumor
tissues, including cyclin B1, caveolin 1, collagen VI, ACC1/pS79,
CHK2, and IGFBP2. The results showed that the data obtained
from Western blot analysis matched those of RPPA assay (Fig. 2,
Fig. S1), demonstrating that the data obtained from RPPA assay
were reliable and can be validated by Western blot analysis.
Neither RPPA assay nor Western blot analysis provided
information about what types of cells, tumor or stromal,
contributed to the differences observed. To determine the cell
types in which the proteins were differentially expressed, we
performed immunohistochemical analyses for five molecules
(ACC-pS79, CHK2, IGFBP2, cyclin B1, and caveolin 1) on
samples that showed difference between normal and tumor tissues.
The results showed that the differences in the expression of all five
molecules were derived from altered expression in cancer cells but
not in stromal cells (Fig. 3). Striking heterogeneity in protein
expression in tumor cells was observed for cyclin B1. Only a
portion of tumor cells were stained strongly with cyclin B1
antibody whereas other tumor cells in the same tumor showed
very low or negative staining for cyclin B1, possibly because of
different status of cell cycles. Cyclin B1 expression is known to be
Figure 1. Signal intensity detected by RPPA. A) Signal intensity (Y axis) for each case (X axis) for molecules of cyclin B1, IGFBP2, and caveolin 1.
B) Alighted distribution of signals in normal and tumor tissues.
doi:10.1371/journal.pone.0031087.g001
Table 2. Levels of proteins in 101 lung cancer cases.*
Molecules Tumor Normal Difference P value
Cyclin B1 0.4960.03 0.2160.03 134% 0.000
COX2 1.3860.22 0.7060.22 96% 0.032
14-3-3Zeta 3.9460.33 2.1560.33 84% 0.003
IGFBP2 0.5860.04 0.3360.04 79% 0.000
KU80 1.1760.05 0.6860.06 74% 0.000
CHK2 0.4960.02 0.2860.02 72% 0.000
ATM 1.6360.04 0.9760.04 69% 0.000
P38-pT180 0.6360.02 0.3960.02 63% 0.000
ACC-pS79 0.5360.02 0.3360.02 61% 0.000
IRS1-pS307 0.9860.04 0.6260.04 60% 0.000
STAT5 1.0960.04 0.7260.04 52% 0.000
S6 0.5260.03 0.3660.03 44% 0.006
SRC 3.6060.05 2.6660.05 35% 0.002
PI3K-p85 0.7660.02 0.5860.02 31% 0.000
mTOR 1.2260.04 0.9460.04 30% 0.000
Caveolin1 7.81624.5 104.7624.5 293% 0.005
CD31 0.2660.02 0.4960.02 248% 0.000
Collagen VI 1.3260.09 2.2760.09 242% 0.000
*Values represent mean6SE.
doi:10.1371/journal.pone.0031087.t002
Aberrant Protein Expression in Lung Cancer
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31087cell cycle dependent and peaked at G2/M [12]. The overexpres-
sion or loss of expression of other molecules was much less
heterogeneous.
Nanjundan et al. recently reported a RPPA profiling analysis on
46 lung cancer cases with 63 proteins or protein phosphorylation
sites and identified several proteins were differentially expressed in
Figure 2. Protein levels detected by Western blot analysis. Cyclin B1, caveolin 1, collagen type VI, ACC-pS79, CHK2, and IGFBP2 in normal and
primary lung tumor tissues were analyzed by Western blot in at least four cases in which RPPA showed signal difference in normal and tumor tissues.
The Western blot results were consistent with those yielded by RPPA.
doi:10.1371/journal.pone.0031087.g002
Figure 3. Examples of aberrant expression of 8 molecules in tumor tissue. Increased expression of ACC-pS79, CHK2, IGFBP2, cyclin B1,
STAT5, ATM, and Ku80, and decreased expression of caveolin 1 in tumor tissues were compared with normal tissues from the same cases shown
withconsistent with findings yielded by RPPA and Western blot analyses. 406Magnification.
doi:10.1371/journal.pone.0031087.g003
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results of current study with that of Nanjundan’s study. The two
studies used completely separate sample sets. All samples used in
Nanjundan’s study were collected before 2000, while the samples
used in this study were collected after 2006. Forty-eight proteins/
protein phosphoryaltaion sites were tested in the both studies.
Eight of eleven (72.7%) markers that were significantly different
between normal and cancer tissues in Nanjundan’s study have
similar significant differences in the current studies. Three
molecules (27.3%) (FAK, b-catenin and AKT) that were
significantly different (p=0.002–0.003) in Nanjundan’s study were
not significant in this study. This result indicates that validation of
RPPA results from separate studies will be important, although the
majority of the differently expressed molecules are consistent in the
two studies.
Three (caveolin-1, cyclin B1 and Src-pY527) of four marker
signature that differentiates NSCLC from normal lung in
Nanjundan’s study were also significantly different between
normal and tumor tissues of the current studies. We therefore
used Nanjundan’s training set (25 cases) to test whether these three
marker signature could be used to differentiate the whole data set
(101 cases) of the current study. The result showed that these three
markers, either alone or in combination, could distinguish tumor
from the normal of the current study with various accuracies,
sensitivities, and specificities (Table 3). In general, a combination
of two or three markers improved either accuracy, sensitivity or
specificity.
Association with Clinical Data
We analyzed whether expression of the 18 molecules listed in
Table 2 in tumor tissues was associated with any clinical
parameters. Statistic analysis revealed that levels of these molecules
in tumor tissues were not significantly associated with clinical stage
or gender. However, expression of Ku80 was significantly higher
in the samples of patients without smoking history than those with
smoking history (p=0.004). Expression of cyclin B1 was
significantly higher in poorly differentiated tumor tissues than in
moderately or well-differentiated tumor tissues (p,0.025). On the
other hand, expression of ATM, Ku80, and S6 was significantly
higher in well-differentiated tumor tissues than in poorly or
moderately differentiated tumor tissues (Fig. 4). When expression
in different histological types was compared, the expressions of
ATM, Ku80, IGFBP2, IRS1-pS307, and S6 were significantly
higher in neuroendocrinal carcinoma than in adenocarcinoma or
squamous cell carcinoma (p,0.05). This result suggests that
expression of certain molecules were dramatically different in
neuroendocrinal tumors when compared with those in adenocar-
cinoma or squamous cell cancer, whereas the levels of the
differentially expressed proteins listed in Table 1 were more or less
similar between adenocarcinoma and squamous cell cancer.
Nevertheless, because of relatively low numbers of neuroendocr-
inal tumors used in this study, it is not clear whether there exists a
specific molecular signature for this type of cancer.
Association with Survival Outcomes
To determine whether levels of those proteins are associated
with clinical outcomes, we performed survival analysis on the
differentially expressed protein markers shown in Table 1, using
Kaplan-Meier method. Briefly, we separate the patients into two
groups based on the median expression value of each individual
marker, designated as high and low expression groups, and then
using the Kaplan-Meier algorithm to compute survival curves for
the two defined groups of each marker. The result showed that the
levels of Stat5 were significantly associated with survival outcomes
when analyzed with both stage I–III patients (p=0.032) and with
stage I patients only (p=0.014) (Fig. 5). Patients with a high level
of Stat5 in their tumor tissues had favorable survival outcomes
when compared with those with a lower level of Stat5, suggesting
that Stat5 could be a useful marker for prognosis of lung cancers.
Discussion
We analyzed molecular differences in protein or protein
phosphorylation levels between normal and lung cancer tissues
in 101 samples by RPPA assay. Of 126 molecules analyzed, we
identified 18 molecules that were dramatically (.30%) and
statistically significant (p,0.05) different between normal and
tumor samples. Western blot analysis and/or immunohistopatho-
logic assays of several molecules validated the results obtained
from RPPA arrays, demonstrating that the results from RPPA
analysis are reliable. Moreover, a comparison with a RPPA study
performed on another of patient samples showed that the results of
RPPA profiling were highly repeatable and consistent in separate
studies with separate set of patient samples. Our results also
indicate that the expression of several molecules in tumor tissues
was associated with smoking history, differentiation, and histo-
pathologic types of lung cancers.
A number of biomarkers identified here are consistent with
those reported in the literature in terms of their altered gene
expressions in tumor tissues, including caveolin 1 [8,9], cyclin B1
[10,11], 14-3-3zeta [14], Stat5 [15], activated p38 [16], and
IGFBP2 [17]. However, for some molecules, some contradictory
findings were reported by others previously. For example, CHK2
expression or its activation was found to be diminished in non-
small-cell lung cancer tumor tissues of a commercially available
tissue array [18], or increased in 50% of surgically resected lung
and breast tumor specimens from untreated patients [19]. We
found that CHK2 expression was increased in both adenocarcima
and squamous cell carcinoma lung tissues, consisting with that
reported by DiTullio et al [19]. Increased COX2 expression was
found in our study, but it was less frequent than reported by Hida
et. al in Japanese patients, where a significant increase in COX2
expression was observed in 70% of invasive adenocarcinoma cases
[20]. Our result was consistent with that reported by Khuri et al,
who observed that only a few cases had strong COX2 expression
in tumor tissues [21].
Interestingly, our results showed that several molecules involved
in DNA damage/repair (ATM, CHK2 and Ku80) were increased
in tumor tissues. Increased mRNA levels of ATM and DNA-PKcs,
but not of Ku80, were detected in tumor tissues when compared
Table 3. Ability of using Nanjundan’s training set to
differentiate the whole data set of this study.
Molecules Accuracy Sensitivity Specificity PPV* NPV*
Cyclin B1 0.755 0.539 0.971 0.948 0.678
Caveolin-1 0.794 0.745 0.843 0.826 0.768
SRC 0.775 0.735 0.814 0.798 0.755
Cyclin B/CAV-1 0.804 0.716 0.892 0.869 0.758
SRC/Cyclin B1 0.848 0.735 0.961 0.949 0.784
SRC/CAV-1 0.814 0.744 0.853 0.840 0.791
SRC/CyclinB1/CAV-1 0.828 0.765 0.892 0.876 0.791
PPV: Positive Predictive Value; NPV: Negative Predicative Value.
doi:10.1371/journal.pone.0031087.t003
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ATM protein expression in primary lung cancer tissues. ATM,
CHK2, and/or Ku80 are regarded as tumor suppressor genes that
are involved in DNA damage response [23,24]. Interestingly,
constitutive activation of ATM/CHK2 pathway was found in p53
mutant cancer cells [19]. The increase of those DNA damage
response/repairing molecules in tumor tissues may reflect the
presence of genome instability in cancer cells, a common feature
that distinguish cancers from normal tissues [25]. It is noteworthy
that overexpression of Ku80 was found in head and neck cancer
and in skin cancer [26,27], and could be caused by activation of
NFkB and COX2 [28]. Alternatively, increased expression of
Ku80 in non-smoker patients or neuroendocrine tumors may
reflect a high demand for repair of double strand breaks by
nonhomologous end-joining in those cancer tissues because Ku80
is critical in this DNA repair pathway. Those molecules may serve
as a marker for cancer therapy targeting the DNA repair pathway
[29]. Because twenty-five patients included in this study had
various neoadjuvant chemotherapies or radiotherapy, we analyzed
whether increased expression of those molecules was associated
with chemo- and radiotherapy. Statistical analysis showed that
increased expression of ATM, CHK2, and Ku80 was not
associated with neoadjuvent chemotherapy or radiotherapy. Thus,
the increased expression of these DNA damage/repair molecules
Figure 4. Protein levels in tumor tissues and association with clinical parameters. Protein levels in tumor tissues detected in RPPA assay
were analyzed for associations with clinical parameters of patients. The molecule that was significantly different in tumors based on clinical
parameters analyzed is shown on the top of each graph. The clinical parameters are shown at the bottom of each graph. The histology and
differentiation diagnoses were based on pathological reports in clinical database. * indicates that the difference was significant when compared with
other groups in the same graph (p,0.05).
doi:10.1371/journal.pone.0031087.g004
Figure 5. Association with Survival Outcomes. Kaplan-Meier analysis on association of Stat5 levels and survival outcomes for Stage I–III (A)
(n=50 for each group), and Stage I only (B) patients (n=33 for STAT5 high group, 34 for STAT5 low group).
doi:10.1371/journal.pone.0031087.g005
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characteristic of primary tumors.
Several deregulated proteins identified here have been investi-
gated as therapeutic targets for cancer therapy. Small molecules or
kinase inhibitors targeting growth factor receptors and the PI3K/
AKT/mTOR, Src/Stat, p38, and ATM/CHK2 pathways were
extensively investigated for cancer treatment, both preclinically
and clinically, including treatment for lung cancers [29–31]. A
recent study showed that inhibition of ATM or CHK2 is sufficient
to sensitize p53-deficient tumor cells, but not p53 wild-type cells,
to genotoxic chemotherapeutic agent cisplatin or doxorubicin
[32], suggesting that combination of cisplatin or doxorubin with
ATM or CHK2 inhibitors could benefit patients carrying p53
mutant tumors. Our results also showed that increased expression
of STAT5 may serve as favorable prognostic biomarker for lung
cancer patients treated with surgery. Although the underlying
mechanisms remain to be further investigated, STAT5 as a tumor
marker of favorable prognosis has been reported for breast cancer
[33–35] and nasopharyngeal cancer [36]. Evidence showed that
STAT5 promotes homotypic adhesion and inhibits invasive
characteristics of human breast cancer cells [34]. Whether the
same occurs to lung cancer cells remain to be further investigated.
However, the significant association of STAT5 with clinical
outcomes, in particular in stage I lung cancer, suggested that
STAT5 might be a useful prognostic biomarker for lung cancer.
Materials and Methods
Human Lung Tissue Specimens
Normal and malignant lung tissue samples were collected
between 2006 and 2009 from surgically removed specimens under
a research protocol Lab-90-020 with informed consent from the
patients. The study was approved by local ethics committee (the
Institutional Review Board at The University of Texas MD
Anderson Cancer Center). The normal tissues were at least 5 cm
away from the edge of corresponding tumors in the same
specimens. Both normal and tumor tissues were collected from
the operating room immediately after specimens were removed
from patients. In all cases, histology quality control was performed
by a thoracic pathologist on tissue sections. Tumor samples were
included in the analysis if the percentage of malignant cells present
in the sample were $70%. Normal lung samples from the same
patients were reviewed to confirm that they contained no
malignant cells. All samples were divided into two portions: one
portion was instantly frozen and stored in liquid nitrogen for
protein extraction; the other portion was fixed in formalin and
embedded in paraffin for routine histological or immunohisto-
chemical examinations. The pairs of matched samples were
harvested, processed, and analyzed at the same time, under the
same protocols.
RPPA Assay
RPPA assay was performed at the Functional Proteomics
Reverse Phase Protein Array Core facility at our institution as we
previously described [37]. Briefly, the tissue samples were washed
twice in ice-cold PBS and then homogenized in RPPA lysis buffer
[1% Triton X-100, 50 mmol/L HEPES (pH 7.4), 150 mmol/L
NaCl, 1.5 mmol/L MgCl2, 1 mmol/L EGTA, 100 mmol/L NaF,
10 mmol/L NaPPi, 10% glycerol, 1 mmol/L Na3VO4, 1 mmol/
L phenylmethylsulfonyl fluoride, and 10 mg/mL aprotinin]. After
centrifugation, the supernatant was collected, and the protein
concentration was determined by routine (e.g., Bradford) assays
and then adjusted to 1–1.5 mg/ml by addition lysis buffer. The
tissue lysates were mixed with 1/4 volume of 46 SDS sample
buffer containing 40% glycerol, 8% SDS, 0.25 M Tris-HCl
(pH 6.8), and 10% (v/v) 2-mercaptoethanol (freshly added). Two-
fold serially diluted tissue lysates (from undiluted to 1:16 dilution)
were printed on nitrocellulose-coated slides (Whatman, Inc.) by
using a GeneTAC G3 arrayer (Genomic Solutions), along with
corresponding positive and negative controls prepared from the
dilution buffer. A total of 126 validated antibodies specific for
proteins or their phosphorylated sites that are involved in various
signaling pathways were available and used in the RPPA (see
Table S1 for antibodies used in this study). Each slide was probed
with a validated primary antibody plus a biotin-conjugated
secondary antibody. The signal was amplified using a DakoCy-
tomation catalyzed system (Dako) and visualized by 3,39-
diaminobenzidine tetrahydrochloride colorimetric reaction. The
slides were scanned, analyzed, and quantified using customized
software, Microvigene (VigeneTech, Inc.), to generate spot
intensity. Signals from each dilution were fitted with the non-
parametric model developed by the Department of Bioinformatics
and Computational Biology at MD Anderson [38]. The protein
concentrations of each set of slides were then normalized and
corrected across samples by the linear expression values, using the
median expression levels of all antibody experiments to calculate a
loading correction factor for each sample, as previously described
[13,37].
Western Blot Analysis
To validate the results from RPPA assays, we performed
Western blot analysis for a subset of molecules that showed
significant difference between normal and cancer tissues. About
40 mg of each frozen tissue sample was washed twice in cold PBS
and homogenized in 0.5 ml ice-cold lysis buffer. Extracts
equivalent to 50–60 mg of the total protein were separated by
10% SDS-polyacrylamide gel electrophoresis, then transferred to
nitrocellulose membranes. The Western blot analysis was
performed as previously described [37]. Antibodies for IGFBP2,
caveolin-1, CHK2 (1C12), and phospho-acetyl-CoA carboxylase
(ACC-pS79) were purchased from Cell Signaling, antibody for
cyclin B1 was from Epitomics, and collagen type VI from Santa
Cruz Biotechnology.
Immunohistochemical Staining and Evaluation
The same antibodies used for Western blot analysis were used
for immunohistochemical staining. Formalin-fixed and paraffin-
embedded tissue sections (5-mm thick) were deparaffinized,
hydrated, and heated in a steamer for antigen retrieval. The
slides were then stained with various antibodies as described
above. Tissues not incubated with a control antibody to mice IgG
instead of a primary antibody were used as a negative control.
Statistical Analysis
Analysis of variance was performed by using STATISTICA
software (StatSoft, Inc.) for comparisons among groups. Student’s t
test was used for comparison between two groups. The diagonal
linear discriminant analysis (DLDA) was used for classification and
prediction of normal and tumor tissues. The survival data will be
analyzed using the Kaplan-Meier method and Cox’s proportional
model. A p-value of ,0.05 was considered statistically significant.
Supporting Information
Figure S1 Protein levels detected by Western blot
analysis in 6 additional cases for IGFBP2 and CHK2.
IGFBP2 and CHK2 in normal (N) and primary lung tumor (T)
tissues were analyzed by Western blot in additional 6 cases in
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tissues. b-actin was used as loading control.
(TIF)
Table S1 Expression difference in adenocarcinoma and
squamous cancer.*
(DOC)
Table S2 Proteins and phosphorylation sites used in
RPPA studies.
(DOC)
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